ATM Haplotypes and Cellular Response to DNA Damage: Association with Breast Cancer Risk and Clinical Radiosensitivity

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8717-8725

  Angèle, Sandra ^a   Romestaing, Pascale ^b   Moullan, Norman ^a   Vuillaume, Michèle ^a   Chapot, Brigitte ^a   Friesen, Marlin ^a   Jongmans, Wim ^a,c   Cox, David G ^a,d   Pisani, Paola ^a   Gérard, Jean Pierre ^b,e   Hall, Janet ^a,f  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f DNA Repair Group   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; MESSENGER RNA; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; ATAXIA TELANGIECTASIA; ATM GENE; BIOSYNTHESIS; BREAST CANCER; BREAST TUMOR; CANCER RADIOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; INTRON; IONIZING RADIATION; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE; MAJOR CLINICAL STUDY; METABOLISM; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION PROTECTION; RADIOSENSITIVITY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LYMPHOCYTES; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIATION TOLERANCE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9144264836     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman, M., Harnik, R., Patanjaki, S. R., Simmons, A., Clines, G. A., Sartiel, A., Gatti, R. A., Chessa, L., Sanal, O., Lavin, M. F., Jaspars, N. G. J., Taylor, A. M. R., Arlett, C. F., Miki, T., Weissman, S. M., Lovett, M., Collins, F. S., and Shiloh, Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (Wash. DC), 268: 1749-1753, 1995.
2. Bakkenist, C. J., and Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature (Lond.), 421: 499-506, 2003.
3. Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer, 3: 155-168, 2003.
4. Swift, M., Morrell, D., Cromartie, E., Chamberlin, A. R., Skolnick, M. H., and Bishop, D. T. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am. J. Hum. Genet., 39: 573-583, 1986.
5. Woods, C. G., Bundey, S. E., and Taylor, A. M. Unusual features in the inheritance of ataxia telangiectasia. Hum. Genet., 84: 555-562, 1990.
6. Su, Y., and Swift, M. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. Ann. Intern. Med., 133: 770-778, 2000.
7. Easton, D. F. Cancer risks in A-T heterozygotes. Int. J. Radiat. Biol., 66: S177-S182, 1994.
8. Geoffroy-Perez, B., Janin, N., Ossian, K., Lauge, A., Croquette, M. F., Griscelli, C., Debre, M., Bressac-de-Paillerets, B., Aurias, A., Stoppa-Lyonnet, D., and Andrieu, N. Cancer risk in heterozygotes for ataxia-telangiectasia. Int. J. Cancer, 93: 288-293, 2001.
9. Inskip, H. M., Kinlen, L. J., Taylor, A. M., Woods, C. G., and Arlett, C. F. Risk of breast cancer and other cancers in heterozygotes for ataxia- telangiectasia. Br. J. Cancer, 79: 1304-1307, 1999.
10. Janin, N., Andrieu, N., Ossian, K., Lauge, A., Croquette, M. F., Griscelli, C., Debre, M., Bressac-de-Paillerets, B., Aurias, A., and Stoppa-Lyonnet, D. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br. J. Cancer, 80: 1042-1045, 1999.
11. Olsen, J. H., Hahnemann, J. M., Borresen-Dale, A. L., Brondum-Nielsen, K., Hammarstrom, L., Kleinerman, R., Kaariainen, H., Lonnqvist, T., Sankila, R., Seersholm, N., Tretli, S., Yuen, J., Boice, J. D., and Tucker, M. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J. Natl. Cancer Inst., 93: 121-127, 2001.
12. Atencio, D. P., Iannuzzi, C. M., Green, S., Stock, R. G., Bernstein, J. L., and Rosenstein, B. S. Screening breast cancer patients for ATM mutations and polymorphisms by using denaturing high-performance liquid chromatography. Environ. Mol. Mutagen., 38: 200-208, 2001.
13. Izatt, L., Greenman, J., Hodgson, S., Ellis, D., Watts, S., Scott, G., Jacobs, C., Liebmann, R., Zvelebil, M. J., Mathew, C., and Solomon, E. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer, 26: 286-294, 1999.
14. Teraoka, S. N., Malone, K. E., Doody, D. R., Suter, N. M., Ostrander, E. A., Daling, J. R., and Concannon, P. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer (Phila.), 92: 479-487, 2001.
15. Dork, T., Bendix, R., Bremer, M., Rades, D., Klopper, K., Nicke, M., Skawran, B., Hector, A., Yamini, P., Steinmann, D., Weise, S., Stuhrmann, M., and Karstens, J. H. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res., 61: 7608-7615, 2001.
16. Maillet, P., Bonnefoi, H., Vaudan-Vutskits, G., Pajk, B., Cufer, T., Foulkes, W. D., Chappuis, P. O., and Sappino, A. P. Constitutional alterations of the ATM gene in early onset sporadic breast cancer. J. Med. Genet., 39: 751-753, 2002.
17. Gatti, R. A., Tward, A., and Concannon, P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol. Genet. Metab., 68: 419-423, 1999.
18. Iannuzzi, C. M., Atencio, D. P., Green, S., Stock, R. G., and Rosenstein, B. S. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int. J. Radiat. Oncol. Biol. Phys., 52: 606-613, 2002.
19. Oppitz, U., Bernthaler, U., Schindler, D., Sobeck, A., Hoehn, H., Platzer, M., Rosenthal, A., and Flentje, M. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int. J. Radiat. Oncol. Biol. Phys., 44, 981-988, 1999.
20. Appleby, J. M., Barber, J. B., Levine, E., Varley, J. M., Taylor, A. M., Stankovic, T., Heighway, J., Warren, C., and Scott, D. Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br. J. Cancer, 76: 1546-1549, 1997.
21. Ramsay, J., Birrell, G., and Lavin, M. Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients. Radiother. Oncol., 47: 125-128, 1998.
22. Shayeghi, M., Seal, S., Regan, J., Collins, N., Barfoot, R., Rahman, N., Ashton, A., Moohan, M., Wooster, R., Owen, R., Bliss, J. M., Stratton, M. R., and Yarnold, J. Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. Br. J. Cancer, 78: 922-927, 1998.
23. Weissberg, J. B., Huang, D. D., and Swift, M. Radiosensitivity of normal tissues in ataxia-telangiectasia heterozygotes. Int. J. Radiat. Oncol. Biol. Phys., 42: 1133-1136, 1998.
24. Romestaing, P., Lehingue, Y., Carrie, C., Coquard, R., Montbarbon, X., Ardiet, J. M., Mamelle, N., and Gerard, J. P. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J. Clin. Oncol., 15: 963-968, 1997.
25. Cox, J. D., Stetz, J., and Pajak, T. F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys., 31: 1341-1346, 1995.
26. Angèle, S., Lauge, A., Fernet, M., Moullan, N., Beauvais, P., Couturier, J., Stoppa-Lyonnet, D., and Hall, J. Phenotypic cellular characterization of an ataxia telangiectasia patient carrying a causal homozygous missense mutation. Hum. Mutat., 21: 169-170, 2003.
27. Fernet, M., Angèle, S., Dork, T., and Hall, J. Variation in radiation-induced apoptosis in ataxia telangiectasia lymphoblastoid cell line. Int. J. Radiat. Biol., 79: 193-202, 2003.
28. Telatar, M., Wang, Z., Udar, N., Liang, T., Bernatowska-Matuszkiewicz, E., Lavin, M., Shiloh, Y., Concannon, P., Good, R. A., and Gatti, R. A. Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening. Am. J. Hum. Genet., 59: 40-44, 1996.
29. Mauget-Faysse, M., Vuillaume, M., Quaranta, M., Moullan, N., Angèle, S., Friesen, M. D., and Hall, J. Idiopathic and radiation induced ocular telangiectasias: the involvement of the ATM gene. Investig. Ophthalmol. Vis. Sci., 44: 3257-3262, 2003.
30. Sandoval, N., Platzer, M., Rosenthal, A., Dork, T., Bendix, R., Skawran, B., Stuhrmann, M., Wegner, R. D., Sperling, K., Banin, S., Shiloh, Y., Baumer, A., Bernthaler, U., Sennefelder, H., Brohm, M., Weber, B. H., and Schindler, D. Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum. Mol. Genet., 8: 69-79, 1999.
31. Maillet, P., Vaudan, G., Chappuis, P., and Sappino, A. PCR-mediated detection of a polymorphism in the ATM gene. Mol. Cell. Probes, 13: 67-69, 1999.
32. Cox, D. G., and Canzian, F. Genotype transposer: automated genotype manipulation for linkage disequilibrium analysis. Bioinformatics, 17: 738-739, 2001.
33. Schneider, S., Roessli D., and Excoffier L. Arlequin ver. 2.000: A software for population genetics data analysis. (2.1). Computer Program, 2000.
34. Jongmans, W., Vuillaume, M., Kleijer, W. J., Lakin, N. D., and Hall, J. The p53-mediated DNA damage response to ionizing radiation in fibroblasts from ataxia-without-telangiectasia patients. Int. J. Radiat. Biol., 74: 287-295, 1998.
35. Gilad, S., Chessa, L., Khosravi, R., Russell, P., Galanty, Y., Piane, M., Gatti, R. A., Jorgensen, T. J., Shiloh, Y., and Bar-Shira, A. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am. J. Hum. Genet., 62: 551-561, 1998.
36. Jongmans, W., Artuso, M., Vuillaume, M., Bresil, H., Jackson, S. P., and Hall, J. The role of Ataxia telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionising radiation. Oncogene, 13: 1133-1138, 1996.
37. Broeks, A., Urbanus, J. H., Floore, A. N., Dahler, E. C., Klijn, J. G., Rutgers, E. J., Devilee, P., Russell, N. S., van Leeuwen, F. E., and van't Veer, L. J. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am. J. Hum. Genet., 66: 494-500, 2000.
38. Chenevix-Trench, G., Spurdle, A. B., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M. A., Scott, C., Pupo, G. M., Dork, T., Bendix, R., Kirk, J., Tucker, K., McCredie, M. R., Hopper, J. L., Sambrook, J., Mann, G. J., and Khanna, K. K. Dominant negative ATM mutations in breast cancer families. J. Natl. Cancer Inst., 94: 205-215, 2002.
39. Stankovic, T., Kidd, A. M., Sutcliffe, A., McGuire, G. M., Robinson, P., Weber, P., Bedenham, T., Bradwell, A. R., Easton, D. F., Lennox, G. G., Haites, N., Byrd, P. J., and Taylor, A. M. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet., 62: 334-345, 1998.
40. Kastan, M. B., Zhan, Q., el Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
41. Artuso, M., Esteve, A., Bresil, H., Vuillaume, M., and Hall, J. The role of the Ataxia telangiectasia gene in the p53, WAF1/CIP1(p21)- and GADD45-mediated response to DNA damage produced by ionising radiation. Oncogene, 11: 1427-1435, 1995.
42. Bebb, D. G., Yu, Z., Chen, J., Telatar, M., Gelmon, K., Phillips, N., Gatti, R. A., and Glickman, B. W. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br. J. Cancer, 80: 1979-1981, 1999.
43. FitzGerald, M. G., Bean, J. M., Hegde, S. R., Unsal, H., MacDonald, D. J., Harkin, D. P., Finkelstein, D. M., Isselbacher, K. J., and Haber, D. A. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat. Genet., 15: 307-310, 1997.
44. Broeks, A., Urbanus, J. H., de Knijff, P., Devilee, P., Nicke, M., Klopper, K., Dork, T., Floore, A. N., and van't Veer, L. J. IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer. Hum. Mutat., 21: 521-528, 2003.
45. Larson, G. P., Zhang, G., Ding, S., Foldenauer, K., Udar, N., Gatti, R. A., Neuberg, D., Lunetta, K. L., Ruckdeschel, J. C., Longmate, J., Flanagan, S., and Krontiris, T. G. An allelic variant at the ATM locus is implicated in breast cancer susceptibility. Genet. Test., 1: 165-170, 1997.
46. Sommer, S. S., Buzin, C. H., Jung, M., Zheng, J., Liu, Q., Jeong, S. J., Moulds, J., Nguyen, V. Q., Feng, J., Bennett, W. P., and Dritschilo, A. Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls. Cancer Genet. Cytogenet., 134: 25-32, 2002.
47. Spurdle, A. B., Hopper, J. L., Chen, X., McCredie, M. R., Giles, G. G., Newman, B., Chenevix-Trench, G., and Khanna, K. No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer. Breast Cancer Res., 4: R15, 2002.
48. Goode, E. L., Dunning, A. M., Kuschel, B., Healey, C. S., Day, N. E., Ponder, B. A., Easton, D. F., and Pharoah, P. P. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res., 62: 3052-3057, 2002.
49. Henderson, B. E., Pike, M. C., Bernstein L., Ross, R. K. Breast cancer. In: D. Schottenfeld and J. F. Fraumeni (eds.), Cancer Epidemiology and Prevention, pp. 1022-1039. New York: Oxford University Press, 1996.
50. Scott, S. P., Bendix, R., Chen, P., Clark, R., Dork, T., and Lavin, M. F. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc. Natl. Acad. Sci. USA, 99: 925-930, 2002.
51. Bonnen, P. E., Story, M. D., Ashorn, C. L., Buchholz, T. A., Weil, M. M., and Nelson, D. L. Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium. Am. J. Hum. Genet., 67: 1437-1451, 2000.
52. Baxter, S. W., Choong, D. Y., Eccles, D. M., and Campbell, I. G. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis (Lond.), 22: 347-349, 2001.
53. Haiman, C. A., Hankinson, S. E., Spiegelman, D., De Vivo, I., Colditz, G. A., Willett, W. C., Speizer, F. E., and Hunter, D. J. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int. J. Cancer, 87: 204-210, 2000.
54. Powell, B. L., van Staveren, I. L., Roosken, P., Grieu, F., Berns, E. M., and Iacopetta, B. Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis (Lond.), 23: 311-315, 2002.
55. Fiets, W. E., van Helvoit, R. P., Nortier, J. W. R., van der Tweel, I., and Struikmans, H. Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients: a prospective, comparative, non-randomised study. Eur. J. Cancer, 39: 1081-1088, 2003.
56. Hall, E. J., Schiff, P. B., Hanks, G. E., Brenner, D. J., Russo, J., Chen, J., Sawant, S. G., and Pandita, T. K. A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J. Sci. Am., 4: 385-389, 1998.
57. Maillet, P., Chappuis, P. O., Vaudan, G., Dobbie, Z., Muller, H., Hutter, P., and Sappino, A. P. A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer. Int. J. Cancer, 88: 928-931, 2000.
58. Mossman, K. L. Radiation protection of radiosensitive populations. Health Phys., 72: 519-523, 1997.
59. Burnet, N. G., Johansen, J., Turesson, I., Nyman, J., and Peacock, J. H. Describing patients' normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescripfions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy. Int. J. Cancer, 79: 606-613, 1998.
60. Turesson, I., Nyman, J., Holmberg, E., and Oden, A. Prognostic factors for acute and late skin reactions in radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys., 36: 1065-1075, 1996.
61. Severin, D. M., Leong, T., Cassidy, B., Elsaleh, H., Peters, L., Venter, D., Southey, M., and McKay, M. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int. J. Radiat. Oncol. Biol. Phys., 50: 1323-1331, 2001.
62. Moullan, N., Cox, D. G., Angèle, S., Romestaing, P., Gerard, J. P., and Hall, J. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk and response to radiotherapy. Cancer Epidemiol. Biomark Prev., in press, 2003.
63. Thorstenson, Y. R., Shen, P., Tusher, V. G., Wayne, T. L., Davis, R. W., Chu, G., and Oefner, P. J. Global analysis of ATM polymorphism reveals significant functional constraint. Am. J. Hum. Genet., 69: 396-412, 2001.
64. Li, A., Huang, Y., and Swift, M. Neutral sequence variants and haplotypes at the 150 Kb ataxia-telangiectasia locus. Am. J. Med. Genet., 86: 140-144, 1999.